285 related articles for article (PubMed ID: 29555094)
1. Pneumococcal and Meningococcal Vaccination among Michigan Children with Sickle Cell Disease.
Wagner AL; Shrivastwa N; Potter RC; Lyon-Callo SK; Boulton ML
J Pediatr; 2018 May; 196():223-229. PubMed ID: 29555094
[TBL] [Abstract][Full Text] [Related]
2. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Advisory Committee on Immunization Practices
MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal vaccination rates in children with sickle cell disease.
Nero AC; Akuete K; Leasure Reeves S; Dombkowski KJ
J Public Health Manag Pract; 2014; 20(6):587-90. PubMed ID: 24253403
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
O'Brien KL; Swift AJ; Winkelstein JA; Santosham M; Stover B; Luddy R; Gootenberg JE; Nold JT; Eskenazi A; Snader SJ; Lederman HM
Pediatrics; 2000 Nov; 106(5):965-72. PubMed ID: 11061761
[TBL] [Abstract][Full Text] [Related]
6. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
[TBL] [Abstract][Full Text] [Related]
8. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
9. [Serious invasive pneumococcal disease in young children: the importance of vaccination].
Haveman LM; Geelen SP; Sanders EA; Wolfs TF
Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1917-20. PubMed ID: 12404904
[TBL] [Abstract][Full Text] [Related]
10. [Survey on vaccination strategies used in different Italian Regions, for the 7-valent conjugate pneumococcal, meningococcal C and varicella vaccines].
D'Ancona F; Alfonsi V; Ciofi degli Atti ML
Ig Sanita Pubbl; 2006; 62(5):483-92. PubMed ID: 17206224
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
12. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska.
Moore MR; Hyde TB; Hennessy TW; Parks DJ; Reasonover AL; Harker-Jones M; Gove J; Bruden DL; Rudolph K; Parkinson A; Butler JC; Schuchat A
J Infect Dis; 2004 Dec; 190(11):2031-8. PubMed ID: 15529269
[TBL] [Abstract][Full Text] [Related]
13. [Acceptance of the new conjugate vaccines. Meningococcal and pneumococcal vaccines, in the cohort born in 1999, in the North Region of Portugal].
De Queirós L; Castro L; Ferreira MC; Gonçalves G
Acta Med Port; 2004; 17(1):49-53. PubMed ID: 15636727
[TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.
Kilpi T; Ahman H; Jokinen J; Lankinen KS; Palmu A; Savolainen H; Grönholm M; Leinonen M; Hovi T; Eskola J; Käyhty H; Bohidar N; Sadoff JC; Mäkelä PH;
Clin Infect Dis; 2003 Nov; 37(9):1155-64. PubMed ID: 14557958
[TBL] [Abstract][Full Text] [Related]
15. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
Sirima SB; Tiono A; Gansané Z; Siribié M; Zongo A; Ouédraogo A; François N; Strezova A; Dobbelaere K; Borys D
Pediatr Infect Dis J; 2017 May; 36(5):e136-e150. PubMed ID: 28403055
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
[TBL] [Abstract][Full Text] [Related]
19. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
[TBL] [Abstract][Full Text] [Related]
20. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine.
Poehling KA; Szilagyi PG; Grijalva CG; Martin SW; LaFleur B; Mitchel E; Barth RD; Nuorti JP; Griffin MR
Pediatrics; 2007 Apr; 119(4):707-15. PubMed ID: 17403841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
